The antibiotic Raxar was approved in November 1997 despite evidence from clinical studies suggesting it could cause several fatal heart-rhythm disruptions. Click on FAQ on Arrhythmia: Raxar, to learn more about this issue.
When Raxar clinical trials came under review by the FDA, a medical officer suspected that two out of four patients who died after taking Raxar in clinical trials possibly suffered heart-rhythm disturbances caused by the drug. FDA officials, however, chose...MORE >>
Featured Articles on Raxar
Browse Books About Drug Litigation